According to the results of the ADAPT AF‐DES trial, a concomitant antiplatelet agent in addition to an OAC should be stopped at a certain time point irrespective of the drug type (i.e., aspirin or P2Y12 inhibitors) [24]. The gene discussed is P2RY12; the disease is atrial fibrillation.